Luyan Pharma Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Jan '23 Jan 1, 2023	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	459.18	576.85	606.3	594.19	415.43	596.92
Cash & Short-Term Investments	459.18	576.85	606.3	594.19	415.43	596.92
Cash Growth	-4.64%	-4.86%	2.04%	43.03%	-30.40%	39.16%
Accounts Receivable	6,555	5,951	5,673	5,849	5,101	3,935
Other Receivables	123.99	108.33	94.59	87.49	117.17	269.68
Receivables	6,679	6,059	5,768	5,937	5,218	4,205
Inventory	2,749	2,865	2,574	2,549	2,275	2,028
Prepaid Expenses	-	0.02	0.25	0.33	0.08	0.25
Other Current Assets	292.08	369.1	370.33	668.17	414.12	378.69
Total Current Assets	10,180	9,870	9,319	9,748	8,322	7,209
Property, Plant & Equipment	2,022	1,928	1,653	1,425	1,037	845.53
Long-Term Investments	60.49	53.41	48.85	34.21	31.3	0.3
Goodwill	289.28	289.28	288.65	289.45	289.45	283.88
Other Intangible Assets	354.57	361.09	355.16	176.93	167.81	113.23
Long-Term Deferred Tax Assets	81.61	75.79	66.37	54.71	43.39	35.11
Long-Term Deferred Charges	25.04	29.04	28.58	28.96	32.82	33.73
Other Long-Term Assets	29.14	31.5	34.46	26.08	68.98	50.73
Total Assets	13,042	12,639	11,794	11,784	9,993	8,571
Accounts Payable	4,304	4,004	3,444	3,258	2,410	2,006
Accrued Expenses	51.67	86.74	98.53	119.54	111.6	103.73
Short-Term Debt	4,037	3,875	3,990	4,455	4,130	3,362
Current Portion of Long-Term Debt	533.71	293.91	171.26	58.25	47.31	21.31
Current Portion of Leases	-	46.67	43.54	37.98	41.69	-
Current Income Taxes Payable	54.9	36.67	43.98	43.47	45.42	44.26
Current Unearned Revenue	27.19	30.72	22.38	31.78	10.57	18.73
Other Current Liabilities	253.55	232.47	211.84	296.53	217.69	353.98
Total Current Liabilities	9,263	8,605	8,026	8,301	7,015	5,910
Long-Term Debt	344.35	648.41	578.63	475.04	226.6	116.94
Long-Term Leases	89.07	87.33	74.33	53.86	40.37	-
Long-Term Unearned Revenue	38.34	38.83	39.76	41.2	41.85	11.5
Long-Term Deferred Tax Liabilities	6.34	6.54	6.81	7.07	7.34	7.63
Other Long-Term Liabilities	37.86	60.14	90.98	114.97	101.17	77.27
Total Liabilities	9,779	9,447	8,817	8,993	7,433	6,124
Common Stock	388.52	388.52	388.52	388.52	388.52	388.52
Additional Paid-In Capital	611.87	617.54	631.05	653.6	656.37	752.07
Retained Earnings	2,236	2,152	1,923	1,676	1,447	1,240
Comprehensive Income & Other	4.04	4.24	3.84	2.82	-0.5	0.49
Total Common Equity	3,240	3,162	2,946	2,721	2,492	2,381
Minority Interest	23.73	29.67	30.68	69.84	68.47	65.96
Shareholders' Equity	3,264	3,192	2,977	2,791	2,560	2,447
Total Liabilities & Equity	13,042	12,639	11,794	11,784	9,993	8,571
Total Debt	5,004	4,951	4,858	5,080	4,486	3,500
Net Cash (Debt)	-4,545	-4,374	-4,252	-4,486	-4,071	-2,903
Net Cash Per Share	-11.81	-11.26	-10.99	-11.57	-10.51	-8.06
Filing Date Shares Outstanding	388.52	388.52	388.52	388.52	388.52	388.52
Total Common Shares Outstanding	388.52	388.52	388.52	388.52	388.52	388.52
Working Capital	917.19	1,265	1,292	1,447	1,307	1,298
Book Value Per Share	8.34	8.14	7.58	7.00	6.41	6.13
Tangible Book Value	2,596	2,512	2,302	2,254	2,034	1,984
Tangible Book Value Per Share	6.68	6.47	5.93	5.80	5.24	5.11
Buildings	-	1,443	1,001	899.38	858.76	816.23
Machinery	-	278.43	259.22	214.51	196.8	182.21
Construction In Progress	-	471.48	616.59	509.06	139.74	57.07

Source: S&P Global Market Intelligence. Standard template. Financial Sources.